Use of zidovudine-sparing HAART in pregnant HIV-infected women in europe: 2000-2009

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 4, 2011, Pages 326-333

  Tariq, Shema ^a,b   Townsend, Claire L ^b   Cortina Borja, Mario ^b   Duong, Trinh ^c   Elford, Jonathan ^a   Thorne, Claire ^b   Tookey, Pat A ^b  

^a CITY UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

antiretroviral agents; congenital abnormalities; highly active antiretroviral therapy; HIV; pregnancy outcome; viral load

Indexed keywords

ABACAVIR; DIDANOSINE; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; ARTICLE; CONGENITAL MALFORMATION; DRUG EXPOSURE; EUROPE; FEMALE; FIRST TRIMESTER PREGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES; TIME FACTORS; VIRAL LOAD; ZIDOVUDINE;

EID: 79959919073     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31821d34d0     Document Type: Article

References (39)

1. Townsend CL, Cortina-Borja M, Peckham CS, et al. Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990-2006. BJOG. 2008;115:1078-1086. (Pubitemid 352000353)
2. European Collaborative Study. Increasing likelihood of further live births in HIV-infected women in recent years. BJOG. 2005;112:881-888.
3. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS. 2001;15:761-770.
4. Duong T, Ades AE, Gibb DM, et al. Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data. BMJ. 1999;319: 1227-1229. (Pubitemid 29511964)
5. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of motherto-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008;22:973-981. (Pubitemid 351652248)
6. European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. AIDS. 2006;20:1419-1427.
7. Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS. 2008;22:289-299.
8. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180. (Pubitemid 24331334)
9. de Ruiter A, Mercey D, Anderson J, et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med. 2008;9:452-502.
10. Gazzard B. British HIVAssociation guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563-608.
11. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9:65-71. (Pubitemid 351228129)
12. Namale L, Zalwngo E, Chidziva E. Pregnancy and pregnancy outcome among women in the DART trial. Paper presented at: 14th Conference in Retroviruses and Opportunistic Infections (CROI); February 25-28, 2007; Los Angeles, CA.
13. Puga AM, Brown ML, Widmayer SM. Abacavir use in HIV-positive pregnant women. Paper presented at: 14th International AIDS Conference; July 7-12, 2002; Barcelona, Spain.
14. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 Through 31 July 2010.Wilmington, NC: Registry Coordinating Centre; 2010.
15. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46:716-723. (Pubitemid 34157656)
16. Torres SM, Walker DM, Carter MM, et al. Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations. Environ Mol Mutagen. 2007;48:224-238. (Pubitemid 46536091)
17. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl] adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004;48:1469-1487. (Pubitemid 38544348)
18. Sabbatini F, Prati F, Borghi V, et al. Congenital pyelectasis in children born from mothers on tenofovir containing therapy during pregnancy: report of two cases [1]. Infection. 2007;35:474-476. (Pubitemid 50005160)
19. Tarantal AF, Castillo A, Ekert JE, et al. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr. 2002;29:207-220. (Pubitemid 34208529)
20. Siberry G, Williams P, Mendez H, et al. Safety of tenofovir use during pregnancy: associations with low birth weight and early growth in HIVexposed uninfected infants. Paper presented at: XVIII International AIDS Conference; July 18-23, 2010; Vienna, Australia.
21. Townsend CL, Willey BA, Cortina-Borja M, et al. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS. 2009;23:519-524.
22. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:458-465.
23. Townsend CL, Willey BA, Cortina-Borja M, et al. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS. 2009;23:519-524.
24. Townsend C, Schulte J, Thorne C, et al. Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States and Europe. BJOG. 2010;117:1399-1410.
25. Nicoll A, Lynn R, Rahi J, et al. Public health outputs from the British Paediatric Surveillance Unit and similar clinician-based systems. J R Soc Med. 2000;93:580-585.
26. Thorne C, Semenenko I, Pilipenko T, et al. Progress in prevention of mother-to-child transmission of HIV infection in Ukraine: results from a birth cohort study. BMC Infect Dis. 2009;9:40.
27. World Health Organisation. International Statistical Classification of Diseases and Related Health Problems, 1989 Revision. Geneva, Switzerland:1992.
28. Katz IT, Shapiro R, Li D, et al. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr. 2010;54:27-34.
29. Health Protection Agency. HIV in the United Kingdom: 2008 Report. London, United Kingdom: Health Protection Agency; 2008.
30. National Study of HIV in Pregnancy and Childhood. 2009. Available at: http://www.nshpc.ucl.ac.uk/. Accessed November 5, 2009.
31. Patel D, Cortina-Borja M, Thorne C, et al. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis. 2007;44:1647-1656. (Pubitemid 46871514)
32. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482-487.
33. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118:e711-e718. (Pubitemid 46089998)
34. Hankin C, Lyall H, Peckham C, et al. Monitoring death and cancer in children born to HIV-infected women in England and Wales: use of HIV surveillance and national routine data. AIDS. 2007;21:867-869. (Pubitemid 46573159)
35. Masters J, Peckham C, Tookey PA. Monitoring cancer and death in uninfected children born to HIV-infected women in England and Wales 1996-2006. Royal College of Paediatrics and Child Health 13th Spring Meeting; March 30-April 2, 2009; York, United Kingdom.
36. Hankin C, Lyall H, Willey B, et al. In utero exposure to antiretroviral therapy: feasibility of long-term follow-up. AIDS Care. 2009;21:809-816.
37. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS. 2003;17:1769-1785. (Pubitemid 37000095)
38. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084-1089. (Pubitemid 29452821)
39. Noguera A, Fortuny C, Munoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics. 2004;114:e598-e603. (Pubitemid 41647668)